Ecopipam Treatment of Tourette Syndrome.

Trial Profile

Ecopipam Treatment of Tourette Syndrome.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Ecopipam (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Sponsors Psyadon Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
    • 24 Jul 2012 Positive interim results from the phase II portion of this trial have been presented in a Psyadon Pharmaceuticals media release.
    • 24 Jul 2012 Status changed from recruiting to discontinued (terminated early), according to a Psyadon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top